Top Markets
Coin of the day
Nicox S.A. Nicox S.A.

Nicox S.A.

COX
Kedudukan dalam Saham #34243
Nicox S.A. is an ophthalmology enterprise operating both within France and... Nicox S.A. is an ophthalmology enterprise operating both within France and globally, focused on developing therapies to safeguard vision and enhance overall eye health. Its leading investigational drug, NCX 470, an innovative nitric oxide-donating prostaglandin analog designed to decrease intraocular pressure in individuals with open-angle glaucoma or ocular hypertension, is currently undergoing Phase 3 clinical trials. Furthermore, the company is progressing NCX 4251, a specialized fluticasone formulation, through a Phase 2b clinical trial for the management of acute exacerbations of blepharitis, as well as NCX 1728. Nicox also provides VYZULTA, a latanoprostene bunod ophthalmic solution for treating open-angle glaucoma or ocular hypertension, and ZERVIATE, a cetirizine ophthalmic solution to relieve ocular itching related to allergic conjunctivitis. The company, established in 1996, has its main office situated in Valbonne, France.
Harga Saham
$0.6379482
Disegerakkan terakhir: 2023-05-22
Modal Pasaran
$5.98M
Perubahan (1 hari)
-0.44%
Perubahan (1 tahun)
0.00%
Negara
FR
Perdagangan Nicox S.A. (COX)

Kategori

Nisbah P/S bagi Nicox S.A. (COX)
Nisbah P/S pada 2026 TTM: 0
Menurut laporan kewangan dan harga saham terkini Nicox S.A., nisbah P/S semasa (TTM) ialah 0. Pada akhir 2026, nisbah P/S syarikat ialah 0.
Sejarah nisbah P/S untuk Nicox S.A. dari 2026 hingga 2026
Nisbah P/S pada akhir setiap tahun
Tahun Nisbah P/S Ubah
Tidak cukup data untuk tarikh yang disediakan.
Nisbah P/S untuk syarikat atau pesaing yang serupa
Syarikat Nisbah P/S Perbezaan Nisbah P/S Negara
10.17 -
US
10.13 -
NL
- -
CH
- -
KR
4.74 -
BE